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TO THE EDITOR
Melanoma is one of the most common
cancers diagnosed in adolescent and
young adults (AYAs) aged 15–39 years,
an age-group deﬁned by the Adolescent
and Young Adult Oncology Progress
Review Group (Adolescent and Young
Adult Oncology Progress Review Group,
2006), and has the potential to result in
the greatest years of life lost of any cancer
(Ekwueme et al., 2011). We previously
reported that non-Hispanic white AYA
males were 55% more likely to die from
melanoma compared with females of the
same age, even after adjusting for tumor
thickness, anatomical site, histologic sub-
type, and presence/extent of metastasis
(Gamba et al., 2013). Over 20 years
(1989–2009), males had signiﬁcantly
poorer survival across all ages o40,
tumor thicknesses (except T2 melanoma,
1.01–2mm), and subtypes, in cases of
cutaneous only disease and regional
metastasis (Gamba et al., 2013). How-
ever, our analyses did not take into
account primary tumor ulceration, a
well-known negative prognostic factor
(Balch et al., 2001), because this inform-
ation was not routinely collected by
cancer registries until 2004, following its
incorporation into AJCC staging in 2002.
A recent cancer registry analysis of 10–
39-year-old melanoma patients (2004–
2008) showed that ulceration rates were
lower than older patients (40–84 years),
but similar by sex and tumor thickness,
except for young females with T4 mela-
noma ⩾4.00mm who had lower ulcera-
tion rates than young males (Richardson
et al., 2014). The few studies that
considered the impact of ulceration on
sex survival disparities were conducted
in selected populations of patients from
clinical trials (Joosse et al., 2012,
2013) or a single institution (Joosse
et al., 2015) or limited by missing inform-
Table 1. Demographic and clinical characteristics of non-Hispanic white
adolescents and young adults 15–39 years of age when diagnosed with a
ﬁrst primary, invasive melanoma, 2004–2011
Total (n= 13,348) Male (n=5,083) Female (n=8,265)
P1
n % n % n %
Primary tumor ulceration status
Absent 11,340 85.0 4,134 81.3 7,206 87.2 o0.001
Present 970 7.3 514 10.1 456 5.5
Unknown 1,038 7.8 435 8.6 603 7.3
Age at diagnosis
15–24 years 2,113 15.8 710 14.0 1,403 17.0 o0.001
25–29 years 2,689 20.1 918 18.1 1,771 21.4
30–34 years 3,529 26.4 1,371 27.0 2,158 26.1
35–39 years 5,017 37.6 2,084 41.0 2,933 35.5
Anatomic site
Head and neck 1,702 12.8 984 19.4 718 8.7 o0.001
Trunk 5,243 39.3 2,229 43.9 3,014 36.5
Upper extremity 2,713 20.3 935 18.4 1,778 21.5
Lower extremity 3,286 24.6 724 14.2 2,562 31.0
Acral 70 0.5 22 0.4 48 0.6
Unknown 334 2.5 189 3.7 145 1.8
Histologic subtype
Superﬁcial spreading 5,160 38.7 1,880 37.0 3,280 39.7 o0.001
Nodular 644 4.8 323 6.4 321 3.9
Rare subtypes 646 4.8 270 5.3 376 4.5
NOS 6,898 51.7 2,610 51.3 4,288 51.9
Breslow depth (in mm)
0.00–1.00 9,596 71.9 3,369 66.3 6,227 75.3 o0.001
1.01–2.00 1,748 13.1 764 15.0 984 11.9
2.01–4.00 7,51 5.6 367 7.2 384 4.6
⩾4.01 368 2.8 219 4.3 149 1.8
Unknown 885 6.6 364 7.2 521 6.3
Presence/extent of metastasis
Cutaneous 11,507 86.2 4,159 81.8 7,348 88.9 o0.001
Regional 953 7.1 514 10.1 439 5.3
Metastatic 260 1.9 170 3.3 90 1.1
Unknown 628 4.7 240 4.7 388 4.7
Subsequent primary cancer
No 12,632 94.6 4,840 95.2 7,792 94.3 0.019
Yes 716 5.4 243 4.8 473 5.7
1chi-squared P-value for differences in proportions of demographic and clinical characteristics
between males and females.
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ation on tumor ulceration (462%) in
population-based data (Joosse et al.,
2011). In addition, no population-based
study has examined whether ulceration
explains the strong disparity in sur-
vival we reported among male AYAs
with melanoma. Therefore, to address this
question, we used the National Cancer
Institute’s SEER18 database, a population-
based cancer registry database covering
~28% of the United States population, to
examine survival for all non-Hispanic
white patients 15–39 years of age when
diagnosed with their ﬁrst primary mela-
noma during 2004–2011 Surveillance,
Epidemiology and End Results (SEER).
Stratiﬁed multivariable Cox propor-
tional hazards regression models were
used to estimate hazard ratios (HRs) and
95% conﬁdence intervals (CIs) to evalu-
ate the association of ulceration status
and sex with melanoma-speciﬁc survi-
val. Multivariable models were adjusted
for age at diagnosis, marital status at
diagnosis, subsequent primary cancer,
anatomic site, histologic subtype, Bre-
slow depth (thickness), and presence/
extent of metastasis (cutaneous, regional
nodal, and distant metastatic disease), as
done previously (Reyes Ortiz et al.,
2007; Aizer et al., 2013; Gamba et al.,
2013). For deceased patients, survival
time was measured from the date of
diagnosis to death from melanoma.
Patients who died of other causes were
censored at the time of death. AYAs
diagnosed by death certiﬁcate/autopsy
only were excluded (n=4). Patients alive
at the study end date (31 December
2012) were censored at this time or last
follow-up. This analysis was approved
by the Cancer Prevention Institute of
California Institutional Review Board.
In 13,348 non-Hispanic white AYA
melanoma patients with a mean follow-
up of 3.8 years (±2.4), we found that
males were almost twice as likely to
have ulcerated tumors (10.1% vs. 5.5%,
Po0.001) than females (Table 1).
Among AYAs with ulcerated tumors,
24.1% of males and 14.7% of females
had T4 melanoma (data not shown in
tables). Primary tumor ulceration was
associated with over a 2-fold increased
risk of death in males and an over 3-fold
increased risk of death in females after
consideration for socio-demographic
and clinical factors (Table 2). However,
the addition of ulceration status to the
multivariable model did not sub-
stantially attenuate the sex disparity
on melanoma-speciﬁc survival (multi-
variate-adjusted HR without ulcera-
tion: 1.46, 95% CI: 1.19–1.78; HR with
ulceration: 1.39, 95% CI: 1.14–1.71),
suggesting that the male/female sur-
vival disparity cannot be explained by
ulceration status alone. Further, we
found that the sex survival disparity
was greatly inﬂuenced by ulceration
status (Pinteraction=0.004). Speciﬁcally,
among AYAs without ulcerated tumors,
AYA males were 59% more likely to die
than AYA females, whereas among
AYAs with ulcerated tumors, there were
no signiﬁcant sex survival differences
(Table 2).
Our ﬁndings suggest that both primary
tumor ulceration and sex are important
prognostic factors in AYAs with mela-
noma, but that ulceration does not fully
explain the worse survival in young
males. AYA males with ulcerated tumors
were more likely than females to have
T4 melanoma in our study, as found
previously (Richardson et al., 2014),
but we did not observe a signiﬁcant
sex survival disparity among AYAs with
ulcerated primary melanoma. However,
among AYAs without primary tumor
ulceration, comprising 481% of AYAs,
markedly increased mortality among AYA
males was observed, even after adjusting
for other prognostic factors.
Both behavioral and biological factors
have been proposed to account for the
survival disparity by sex across mela-
noma patients of all ages (Nosrati and
Wei, 2014), with this study adding to
the growing literature speciﬁc to AYAs,
in whom biology may have a more
prominent role than behavioral factors
(Fisher and Geller, 2013; Gamba et al.,
2013). Although the biological basis is
unknown, biological factors proposed to
inﬂuence these sex survival differences
include sex hormones, immune homeo-
stasis and regulation, response to ultra-
violet radiation, vitamin D metabolism,
and oxidative stress response (Fisher
and Geller, 2013; Nosrati and Wei,
2014). There is also growing evidence
for the tumor suppressive role of the
long non-coding RNA, Xist, which is
required for X-chromosome inactivation
(Yildirim et al., 2013; Chu et al., 2015).
Our population-based study had a
large, representative series of melanoma
patients, but also the potential for varia-
tion in interpretation of primary tumor
ulceration by pathologists or coding
by registrars (Richardson et al., 2014);
strengths include the low (7.8%) rate
of missing ulceration status in the
cancer registry data. Future studies
with longer follow-up should continue
to investigate the possible biological
mechanisms that account for sex differ-
ences in melanoma survival, as they may
Table 2. Melanoma-speciﬁc survival among non-Hispanic white adolescent and young adults 15–39 years of age
when diagnosed with ﬁrst primary melanoma, 2004–2011
Primary tumor ulceration status
No. of deaths Stratiﬁed analysis HR1 (95% CI)
Male Female Males only Females only Male vs. Female2
Absent 111 64 Reference Reference 1.59 (1.15–2.19)
Present 107 54 2.45 (1.74–3.44) 3.22 (2.03–5.12) 1.10 (0.77–1.57)
Unknown 89 44 1.72 (1.18–2.52) 2.33 (1.44–3.75) 1.24 (0.85–1.81)
Abbreviations: CI, conﬁdence intervals; HR, hazard ratio.
1HR and 95% CI adjusted for age at diagnosis, marital status at diagnosis, subsequent primary cancer, anatomic site, histologic subtype, Breslow depth, and
presence/extent of metastasis.
2P for interaction between ulceration status and sex= 0.004.
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inform novel prevention and treatment
strategies.
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TO THE EDITOR
Basal cell carcinomas (BCCs) are the most
common cancers in the United States,
with an annual national incidence of ~2
million (Lomas et al., 2012). Although the
majority are localized to the skin and
cured by surgery, in rare cases, they can
progress to advanced and metastatic
tumors that result in severe morbidity
and death. BCCs are typically caused
by activating mutations in the sonic
hedgehog (HH) pathway, most
commonly through loss of the receptor
Patched1 (PTCH1) or activation of the
G-protein-coupled receptor Smoothened
(SMO; Epstein, 2008). Here, we report
the presence of Kinastrin (kinetochore-
localized astrin/SPAG5 binding protein
(KNSTRN)) mutations in BCC. KNSTRN
encodes a kinetochore-associated protein
that is an essential component of the
mitotic spindle and is required for faith-
ful chromosomal segregation during mito-
sis (Fang et al., 2009). It is expressed
in a broad range of tissues, including
skin, and its mutations have been
detected in both squamous-cell carci-
noma (SCC) and melanoma, leading to its
recent classiﬁcation as an oncogene (Lee
et al., 2014).
In order to elucidate the role of
KNSTRN in BCC, we interrogated 18Accepted article preview online 8 September 2015; published online 24 September 2015
Abbreviations: BCC, basal cell carcinoma; CNV, copy-number variation; COSMIC, Catalogue of Somatic
Mutations in Cancer; HH, sonic hedgehog pathway; KNSTRN, kinetochore-localized astrin/SPAG5
binding protein; PTCH1, patched 1; SCC, squamous-cell carcinoma; SMO, smoothened; TP53, tumor
protein 53
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